About us

The Benefit-Risk SIG was set up at the start of 2012 to help support those involved in this fast evolving area. The main aims of the SIG are:

  • To understand how best to apply Benefit-Risk Methodologies across the Pharmaceutical Industry
  • To discuss and make recommendations on key methodological issues
  • To share examples of how Benefit-Risk has been used within pharmaceutical companies
  • To share external information including new developments around Benefit-Risk – See more here

This working group is part of the PSI and EFSPI. Please contact Alexander Schacht (schacht_alexander@lilly.com) if you would like to become a member.